Equipment and Processing Report, Jan 19, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Equipment and Processing Report, Jan 19, 2011
Production Lines
What's More Important, the Process or the Product?
By Erik Greb
Improvements in analytical techniques may call for a re-evaluation of the biopharmaceutical industry saying that "the process is the product."
In the Mixer
The Role of Bioburden in the Contamination-Control Plan
By Scott Sutton
A company's contamination-control plan is an important document designed to formalize the rationale, methods, and validation of contamination-control procedures in a manufacturing facility. The author describes the role of bioburden in the contamination-control plan.
Troubleshooting
Insufficient Product Yield
An industry expert answers a reader's question about using a volumetric dry-material feeder and jet mill to create a finished product.
Editor's Picks
January 2011 Editor's Picks: Products from AdvantaPure and NETZSCH Premier Technologies
PharmTech's monthly newsletter, Equipment and Processing Report, reviews the Editor's Picks for the January 2011 edition from AdvantaPure and NETZSCH Premier Technologies.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here